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ABSTRACT: Background: Complex parkinsonism is
the commonest phenotype in late-onset PLA2G6-
associated neurodegeneration.
Objectives: The aim of this study was to deeply charac-
terize phenogenotypically PLA2G6-related parkinsonism
in the largest cohort ever reported.
Methods: We report 14 new cases of PLA2G6-related
parkinsonism and perform a systematic literature review.
Results: PLA2G6-related parkinsonism shows a fairly dis-
tinct phenotype based on 86 cases from 68 pedigrees.
Young onset (median age, 23.0 years) with parkinsonism/
dystonia, gait/balance, and/or psychiatric/cognitive symp-
toms were common presenting features. Dystonia
occurred in 69.4%, pyramidal signs in 77.2%, myoclonus
in 65.2%, and cerebellar signs in 44.6% of cases. Early
bladder overactivity was present in 71.9% of cases. Cog-
nitive impairment affected 76.1% of cases and psychiatric
features 87.1%, the latter being an isolated presenting
feature in 20.1%. Parkinsonism was levodopa responsive
but complicated by early, often severe dyskinesias. Five
patients benefited from deep brain stimulation. Brain mag-
netic resonance imaging findings included cerebral
(49.3%) and/or cerebellar (43.2%) atrophy, but mineraliza-
tion was evident in only 28.1%. Presynaptic dopaminergic
terminal imaging was abnormal in all where performed.
Fifty-four PLA2G6 mutations have hitherto been associ-
ated with parkinsonism, including four new variants
reported in this article. These are mainly nontruncating,
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which may explain the phenotypic heterogeneity of
childhood- and late-onset PLA2G6-associated neu-
rodegeneration. In five deceased patients, median disease
duration was 13.0 years. Brain pathology in three cases
showed mixed Lewy and tau pathology.
Conclusions: Biallelic PLA2G6 mutations cause early-
onset parkinsonism associated with dystonia, pyramidal
and cerebellar signs, myoclonus, and cognitive impair-
ment. Early psychiatric manifestations and bladder
overactivity are common. Cerebro/cerebellar atrophy are
frequent magnetic resonance imaging features, whereas
brain iron deposition is not. Early, severe dyskinesias are
a tell-tale sign. © 2021 The Authors. Movement Disorders
published by Wiley Periodicals LLC on behalf of Interna-
tional Parkinson and Movement Disorder Society
Key Words: NBIA; parkinsonism; PLA2G6; PLAN; sys-
tematic review
PLA2G6 encodes the calcium-independent phospho-
lipase A2β (iPLA2β), which hydrolyzes membrane phos-
pholipids and lysophospholipids, thereby regulating
membrane homeostasis and generating lipid second
messengers involved in cell proliferation, Ca2+ signal-
ing, mitochondrial dynamics, and apoptosis.1,2
Biallelic PLA2G6 mutations were initially associated
with infantile (INAD) and atypical neuroaxonal dystro-
phies (ANADs).3,4 INAD presents with psychomotor
regression/delay between 6 and 36 months, and its clinic
picture includes early axial hypotonia progressing to
spastic tetraparesis, intellectual disability, strabismus,
optic atrophy, and axonal sensorimotor neuropathy, with
death occurring by age 10 years because of bulbar dys-
function.3,5,6 ANAD usually manifests between 1.5 and
6.5 years with prominent language difficulty and autistic-
like traits, along with cerebellar, pyramidal, and dystonic
features. ANAD shows fairly slow progression during
early childhood and rapid deterioration at the turn of the
first decade of life.4 Neuroradiological findings in INAD/
ANAD encompass cerebellar atrophy, cerebellar cortical
magnetic resonance imaging (MRI)-T2 hyperintensity,
iron deposition in the globus pallidus (GP) and/or sub-
stantia nigra (SN), white matter abnormalities, vertically
oriented splenium of the corpus callosum, claval hyper-
trophy, and thinning of the optic pathway.7 Axonal
degeneration with distended axons (spheroid bodies)
throughout the central and peripheral nervous systems is
the pathological hallmark of INAD/ANAD.3,4,6
In 2009, PLA2G6 was linked to dystonia-parkinsonism
with onset in the second to third decades of life.8 Since
then, additional phenotypes manifesting later than INAD/
ANAD have been described, including parkinsonism either
isolated or combined with other neurological/psychiatric
features,9,10 ataxia,11,12 and spastic paraplegia.13,14
Growing evidence suggests that PLA2G6-associated
neurodegeneration (PLAN) is a phenotypic contin-
uum.12,15 For instance, childhood-onset phenotypes and
PLA2G6-related parkinsonism share Lewy and tau
pathology.16 Equally, there are unsolved questions about
PLAN, particularly late-onset phenotypes. Controversies
remain regarding why PLA2G6 mutations cause such a
wide phenotypic spectrum, and why the same mutation
leads to different phenotypes, even in the same pedigree.
Little is known about late-onset PLAN progression
because ongoing natural history studies mainly focus on
INAD.17,18 Finally, treatments with disease-modifying
potential have not hitherto been explored in late-onset
PLAN.19 Some PLAN cases show brain iron deposition,
thus raising the option of chelation therapy, as in panto-
thenate kinase-associated neurodegeneration.20 More
promisingly, small molecule therapies are under investi-
gation in cell and murine models, and a viral vector-
based gene therapy has been tested in the PLA2G6-
INAD mouse with encouraging results and is
approaching completion of preclinical studies,15,21 as
reviewed elsewhere.19 Promptly recognizing PLA2G6-
related phenotypes, in particular PLA2G6 parkinsonism
among early-onset parkinsonism from different etiolo-
gies, may therefore have considerable therapeutic impli-
cations in the not-too-distant future.
We report 14 new cases of PLA2G6-associated parkin-
sonism carrying 13 different mutations, 4 of which are
novel. By merging data from this series and a systematic
literature review, we deeply characterize phenotypically
and genotypically PLA2G6-related parkinsonism, high-
light clinicoradiological hints for diagnosis, outline its
natural history, and discuss poorly understood issues in
late-onset PLAN.
Subjects and Methods
We identified new cases of PLA2G6-associated par-
kinsonism from six centers and systematically searched
PubMed (14/03/2021) for parkinsonism in genetically
confirmed PLAN published since 2006 (discovery
paper). The search strategy was “PLA2G6” AND
“parkins*,” with no language restriction. Additional
references from relevant articles were identified and
reviewed. According to the search strategy, the system-
atic review was driven by the presence of parkinsonism
in genetically confirmed PLAN cases; thus, subsequent
results were not restricted to any age at symptom onset.
Only cases carrying biallelic PLA2G6 mutations with
individual information were included. Predefined cate-
gories for data extraction were sex; ethnicity; age and
symptom(s) at onset; age at last assessment; different
neurological and psychiatric symptoms/signs; findings
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from laboratory, neuroimaging, and other investiga-
tions; family history; genotype; and treatment response.
Neuropathology specimens available at Queen Square
Brain Bank and videos of published cases were
reviewed. Phenotypic features were recorded as non-
missing if explicitly stated to be present/absent.
PLA2G6 variants were (re-)annotated in reference to
transcript NM_003560.4. Combined Annotation
Dependent Depletion, PolyPhen-2, Sorting Intolerant
From Tolerant, MutationTaster, and Protein Variation
Effect Analyzer were used to predict the impact of mis-
sense mutations on the protein structure and function.
We assessed sequence conservation across species using
Genomic Evolutionary Rate Profiling and/or visual mul-
tiple sequence alignment (Clustal Omega).22 gnomAD
and ClinVar were retrieved on August 11, 2021. Muta-
tions were finally classified according to American Col-
lege of Medical Genetics and Genomics guidelines.23
Descriptive statistics were performed using IBM SPSS
Statistics. Results are provided as valid percentages
(ie, counts divided by the total number of nonmissing
observations) for dichotomous variables and median
with interquartile range (IQR; weighted average) for
continuous variables.
Results
Clinicogenetic features of 14 new cases of PLA2G6 par-
kinsonism from 12 families are summarized in
Table 18,12,24 and detailed in Supporting Information Files 1,
2, and 3. Progression of clinical manifestations over time in
the new cases is outlined in Supporting Information File 4.
They carried 13 PLA2G6 mutations, including 4 of which
are novel (Table 2).3,7,8,12,14,16,24-39 We screened for eligibil-
ity 162 references from PubMed search results (n = 136)
and their reference lists (Supporting Information File 5). We
found 40 references reporting 72 additional cases from
57 pedigrees and carrying 46 different PLA2G6 mutations.
Predefined data were extracted (Supporting Information
File 3).7-10,12-14,16,24,25,29-32,35,39-63 Overall, 86 cases from
68 kindreds contributed to the phenogenotypic description
of PLA2G6-related parkinsonism.
Phenotype
The cohort included 45 female patients (52.3%;
Fig. 1A). Ethnicity was traceable in 84/86 (97.7%;
Fig. 1B). Developmental milestones were unremarkable in
42/45 (93.3%) patients, whereas one case experienced
long-term toe-walking,16 one slower development,41 and
one unspecified developmental delay stabilized by ther-
apy.44 Convergent strabismus was noticed in case 10 since
age 2 years.
Median age of symptom onset calculated for 81/86
(94.2%) cases was 23.0 years (IQR, 11.0; Fig. 1C),
with 70/83 (84.3%) patients having onset before age
31 years. Median age at last assessment determined in
67/86 (77.9%) cases was 31.0 years (IQR, 12.0).
Median disease duration at last assessment in 68/86
(79.1%) cases was 7.0 years (IQR, 11.75). Presenting
symptoms are summarized in Fig. 1D. Extrapyramidal
features (parkinsonism/dystonia; 38/79, 48.1%), gait/
balance problems (29/79, 36.7%), and psychiatric/
cognitive issues (25/79, 31.6%), either alone or com-
bined, were the most common manifestations at onset.
Psychiatric manifestations (eg, severe anxiety, major
depression, psychosis) were isolated presenting symp-
toms in 16/79 (20.2%) patients,10,16,25,29,44,57,59,60
foot dragging was the sole initial complaint in 8/79
(10.1%),8,9,24,40,45,46,63 and urinary incontinence was
a major symptom at onset in 2/79 2.5%).16,50
Parkinsonism, either isolated or combined with other
neurological/psychiatric features (Fig. 1E), started at a
median age of 25.0 years (IQR, 9.25) and was present at
onset or within 1 year in 45/68 (66.2%) patients. In the
remaining 23 cases, the median time interval between
symptom onset and onset of parkinsonism was 3.0 years
(IQR, 9.00). Hyposmia/anosmia was not reported as a
premotor symptom in any of our cases and was men-
tioned only once in the literature.55 Parkinsonism pres-
ented as an akinetic-rigid syndrome in nearly half of the
cases, whereas 36/67(53.7%) patients had rest tremor
mostly affecting the upper limbs and/or rarely the lower
limbs.56-58 Parkinsonian signs were asymmetric at onset
in 40/50 (80.0%) cases. Hallucinations were reported in
16/30 (53.3%) cases, either visual (9), auditory (2), or
both (4). Delusions were present in 11/23 (47.8%).
Sleep disturbances, including sleep fragmentation and
acting out dreams, were mentioned in 10/16 (62.5%)
patients. Polysomnography was available in cases
1 and 14, showing prolonged rapid eye movement
phase and sleep apnea, respectively.
Dystonia was present in 50/72 cases (69.4%; Fig. 1E).
When specified, dystonia was reported to affect the
limbs only (17 cases) or to be generalized (8). Trunk
dystonia was frequent, with overt opisthotonus in four
cases. Cranial dystonia was reported in 11 patients
(facial grimacing in 5, oromandibular dystonia in
4, blepharospasm in 3). Myoclonus, spontaneous and/or
stimulus sensitive, was reported in 15/23 (65.2%) cases
at any point in the disease course but never at onset
(Fig. 1E). In case 2, we documented the cortical origin
of myoclonus on neurophysiology (electromyography
bursts duration < 50 ms, electroencephalographic dis-
charges time-locked to individual myoclonic jerks
detected with jerk-locked back averaging). Pyramidal
signs were detected in 44/57 subjects (77.2%; Fig. 1E).
Reduced muscle strength was mentioned in only one
case.29 Cerebellar signs were observed in 29/65 cases
(44.6%; Fig. 1E), including mild dysmetria, gait ataxia,
or gaze-evoked nystagmus. Postural and/or action
tremor was mentioned in 10 cases.
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Gait abnormalities were constantly present early in
the disease course (Fig. 1E). When details were avail-
able (39 cases), gait was described as having parkinso-
nian (46.2%), ataxic (30.8%), pyramidal (23.1%),
dystonic (17.9%) features, either alone or in combina-
tion. Freezing of gait was mentioned in three patients.
Postural impairment was also constantly reported
(Fig. 1E), causing loss of walking independence with a
FIG. 1. Descriptive statistics of the whole cohort with PLA2G6-related parkinsonism, including new and previously published cases. The number of
cases for which the information was available (nonmissing observations) is indicated by n in (A)–(D) and by fractions’ denominator in (E). (A) Sex distri-
bution. (B) Ethnicity: number of cases according to ethnicity are reported in brackets. (C) Age at symptom onset according to age group. *Two addi-
tional cases with unspecified age of onset of parkinsonism before the age of 31 years.41 (D) Symptom(s) at onset according to major descriptive
categories. (E) Phenotypic spectrum of PLA2G6-associated parkinsonism with clinical features (yellow bars), brain magnetic resonance imaging (MRI)
findings (green bars), and findings on presynaptic dopaminergic terminal imaging (blue bar). LD, levodopa; WMA, white matter abnormalities. [Color fig-
ure can be viewed at wileyonlinelibrary.com]
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median time interval of 3.0 years (IQR, 3.0) after symp-
tom onset.
Dysautonomia was present in 25/35 (71.4%) patients
(Fig. 1E), with symptoms of bladder overactivity and/or
urinary incontinence reported in 71.9% of cases and
constipation in 50%. Orthostatic hypotension was
mentioned in two cases.42,43
Cognitive impairment was documented early in the
disease course in 51/67 (76.1%) patients (Fig. 1E). Psychi-
atric comorbidity was present in 61/70 (87.1%)
cases (Fig. 1E), including depression (80.0%), anxiety
(79.2%), and signs of frontal lobe impairment (87.0%),
encompassing, among others, apathy, paranoid thoughts,
aggressive behaviors, and emotional lability.
Eye movement abnormalities were reported in 24/41
(58.5%; Fig. 1E) cases, with fragmented pursuit and/or
reduced gaze range in the vertical plan being the most fre-
quent. Eyelid-opening apraxia was reported in six
cases.8,24,25,55 Dysarthria was described in 29/30 (96.7%;
Fig. 1E) cases. Swallowing difficulties were reported in
17/20 (85.0%) cases (Fig. 1E) and, in 6 cases with details
available,7,8,12,16,24,30,51 overt dysphagia and/or the need
of percutaneous endoscopic gastrostomy occurred a
median interval of 10 years (IQR, 7.0) after symptom
onset. Sensory signs were reported in one case.16 General-
ized seizures occurred in five patients some years into the
disease course.8,16,24,31,39 Oculogyric crises were reported
in four cases.10,30,58
Parkinsonism responded to levodopa in 71/73 (97.3%)
cases. Levodopa-induced dyskinesias were reported in
46/57 (80.7%) cases and appeared within the first year of
treatment in most cases, even with low levodopa doses
(≤300 mg/day). In some cases, levodopa caused behavioral
changes with psychotic manifestations, or dystonic reactions
mainly affecting the oromandibular or cervical region. In
17/18 cases, dopamine agonists had a beneficial response;
however, some cases experienced negative side effects,
including psychosis and hypersexuality. Response to other
pharmacological treatments is detailed in Supporting Infor-
mation File 3. Four patients underwent bilateral deep brain
stimulation (DBS) of the subthalamic nucleus (STN) with
excellent outcome,57 and one patient underwent bilateral
DBS of the GP internus (GPi; case 1) with improvement of
trunk dystonia and control of levodopa-induced dyskine-
sias. One patient underwent unilateral pallidotomy with
transient relief of motor fluctuations.52,53
Five patients died at a median age of 36.0 years
(IQR, 13.0), showing a median disease duration of
13.0 years (IQR, 14.5).
Brain MRI was available in 82/86 (95.3%) patients.
Cerebral atrophy was reported in 34/71 cases (47.9%),
being described as mild to moderate in severity and
generalized or mainly involving the frontotemporal
lobes (Fig. 1E; Supporting Information File 2B,F,G,L,
O). Mild to marked cerebellar atrophy affecting the
vermis and/or the hemispheres was observed in 32/81
(39.5%; Fig. 1E; Supporting Information File 2B,G,L,
N) cases. In 21/82 (25.6%) cases, there was evidence of
iron deposition on MRI-T2/T2*/SWI sequences
(Fig. 1E; Supporting Information File 2D–I). Interest-
ingly, iron deposition was not detected in 15 cases in
which T2*/SWI sequences were performed (Fig. 1E;
Supporting Information File 2A–P). White matter T2
hyperintensities were reported in three cases,8,24,40,56
mainly in the frontal lobes. Additional findings on brain
MRI (Fig. 1E) were claval hypertrophy in four
patients,7,12,14,31,56 vertically oriented corpus callosum
in two,14,31 and the swallow tail sign in two.61 Follow-
up brain MRI scans were available in seven patients,
showing progression of cerebral and/or cerebellar atro-
phy in three cases,16 as well as appearance of iron
deposition in two.8,24,51 In three patients, CT scan
excluded MRI-T2/SWI hypointensity corresponding to
basal ganglia calcifications. Spine MRI, available in
eight cases, showed no signal abnormalities from the
spinal cord.
Dopamine imaging with presynaptic tracers was
available in 37/86 cases (43.0%) and invariably abnor-
mal (Fig. 1E; Supporting Information File 2C,E,H,M,
Q). In one patient, 11C-raclopride (RAC)-positron emis-
sion tomography for postsynaptic receptor function
revealed increased RAC uptake in the putamen more
than in the caudate.25 18F-fluorodeoxyglucose-positron
emission tomography, performed in seven cases,
showed global hypometabolism of cerebral cortex and
cerebellum in one case,47 hypometabolism in the
frontoparietal regions in three,29 and hypometabolism
in the temporoparietal regions or parieto-occipital lobes
in one case each.10,39
EEG was abnormal in four of eight cases where
reported, with diffuse slowing and multifocal epilepti-
form abnormalities a few years into the disease
course.16,24,31,59 Nerve conduction studies were per-
formed in seven patients, showing signs of distal sen-
sory neuropathy in two.7,16 Four patients with
pyramidal signs underwent motor-evoked potentials
(MEPs), which showed delayed central motor conduc-
tion time in two cases, including case 1.50 In case
12, motor-evoked potential was abnormal despite the
absence of clinically detectable pyramidal signs.
Retinopathy was excluded by ophthalmological
assessment in five cases.8,24,25,40,63 Visual-evoked
potentials were normal in three cases.8,24,29
CSF analysis revealed decreased homovanillic acid in
4/13 (30.8%) cases,8,24,29 2 of which had subsequent
normal phenylalanine loading test.8,24
Genotype
Parental consanguinity was reported in 35/64
(54.7%) cases. Overall, 46/86 (53.5%) patients carried
homozygous variants in PLA2G6, whereas segregation
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analysis revealed that 40/86 (46.5%) were compound
heterozygotes.
The new cases carried 13 distinct PLA2G6 muta-
tions, including four novel missense variants
(c.956C>T, c.1924A>G, c.2311G>A, and c.1937>T),
four missense variants previously reported in only
childhood-onset phenotypes (c.1061T>C, c.673C>T,
c.1021G>A, and c.1898C>T), and one nonsense
(c.2370T>G) and three missense variants (c.238G>A,
c.2222G>A, and c.2239C>T) described in both
childhood- and late-onset phenotypes (Table 2). The
novel variants were either absent (n = 2) or exceedingly
rare (minor allele frequency, MAF < 0.1%; n = 2) in
gnomAD, highly conserved across species, and
predicted pathogenic by at least four predetermined
prediction tools (Table 2). Among variants previously
reported in only childhood-onset phenotypes, the vari-
ant c.1061T>C was in compound heterozygosity with
FIG. 2. Overview of genetic variants and protein changes associated with PLA2G6-related parkinsonism. Large box: schematic of the PLA2G6 gene
and its product with genetic variants and corresponding protein changes associated with parkinsonism. Upper part: ideogram of chromosome 22 show-
ing the localization of the PLA2G6 gene. Middle part: schematic of the PLA2G6 gene with 54 mutations linked to parkinsonism. Lower part: schematic
of the PLA2G6 protein product (iPLA2β) with predicted protein changes. The protein structure encompasses seven ankyrin repeats (light blue), a
proline-rich motif (yellow), a glycine-rich nucleotide binding motif (light blue), a lipase motif (pink), and a proposed C-terminal Ca2+-dependent calmodu-
lin binding domain (dark blue). Small boxes: structural distribution of coding mutations in PLA2G6. (A) Crystal structure of the dimeric iPLA2β complex,
displayed in association with the phospholipid bilayer cell membrane. The dimer consists of catalytic domains, which firmly interact through an exten-
sive interface, and ankyrin domains, which are oriented outward from the catalytic core and anchor the protein to the membrane in its inactive state.1
The active site of each subunit is proposed to adopt an open conformation for phospholipids to access the catalytic regions in the absence of mem-
brane interaction. Monomer 1 shows domain organization, with the ankyrin repeats colored light blue and the phospholipase domain colored pink. (B)
Distribution of coding mutations in PLA2G6 across the functional domains of iPLA2β, showing localization with the ankyrin (left-hand inset, blue) and
phospholipase domains (right-hand inset, pink). Protein coordinates are derived from Malley et al.,1 protein database file 6AUN. Images are generated
using UCSF Chimera.71 UTR, untranslated region. [Color figure can be viewed at wileyonlinelibrary.com]
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another missense variant in a case of neurodegeneration
with brain iron accumulation (NBIA)3 and with non-
sense and frameshift variants in two INAD cases.3,16
The variant c.238G>A was found in compound hetero-
zygosity with a nonsense variant in an NBIA case3 and
in homozygosity in two cases (onset 8 and 14 years,
respectively).25,26 The variant c.1021G>A was previ-
ously found in compound heterozygosity with a mis-
sense variant in two siblings with INAD3 and in
homozygosity in another INAD case,36 whereas the
FIG. 3. Postmortem findings in the brain and spinal cord of a patient carrying c.109C>T and c.1078-3C>A mutations in PLA2G6 (previously publi-
shed).16 (A) In the cerebellar cortex, there is a severe depletion of granule cells (yellow arrow), prominent gliosis in the molecular layer (red asterisk), and
to a lesser extent depletion of the Purkinje cells (blue asterisk), shown on hematoxylin and eosin (H&E)-stained section. (B) The dentate nucleus in the
cerebellum, demonstrated on H&E-stained section. (C) The inferior olivary nucleus in the medulla (preparation immunostained for nonphosphorylated
TDP43) shows only mild gliosis and no significant neuronal loss. (D) The dorsal vagus nerve nucleus, although containing Lewy bodies (not shown),
does not demonstrate any severe neuronal depletion. (E) Transverse H&E-stained section of the spinal cord at the lumbar level shows (F) that the pos-
terior nerve roots are much more prominently depleted of myelinated fibers (G) compared with the anterior nerve roots. (H) In the posterior horns, there
are frequent, variably large axonal spheroids (green arrow, H&E-stained section), but no apparent Lewy body or tau pathology (not shown). (I) Lewy
bodies are particularly numerous in the less atrophic medial part of the substantia nigra, (J) in the CA2 region of the hippocampus, and (K) across the
deep layers of all the neocortical regions (I, J, immunostained for α-synuclein; K, immunostained for p62; positive inclusions in K are highlighted with
blue arrow). (L, M) Occasional isolated neuropil threads (L) and rare tangles (M) are seen in the medial temporal lobe. Scale bars: 300 μm (A); 100 μm
(B–D, F–J, L, M); 2.5 mm (E); 550 μm (K). [Color figure can be viewed at wileyonlinelibrary.com]
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variant c.673C>T was detected in the homozygous state
in two kindreds with childhood-onset cases.27 Among
the variants reported in both childhood- and late-onset
phenotypes, the nonsense variant c.2370T>G was in
compound heterozygosity with a missense variant in
case 7 (age at onset: 25 years) and found in the homo-
zygous state in an INAD case3 and in compound het-
erozygosity with another nonsense variant (c.1674del)
in two sisters with INAD.33 Overall, these observations
suggest a gradient in the age of onset and phenotype
severity reflecting variants’ impact on the transcript.
The number of PLA2G6 mutations associated with par-
kinsonism increases to 54 (Table 2, Fig. 2). These included
46 nontruncating (44 missense and 2 in-frame deletions)
and 8 truncating (4 splicing, 2 nonsense, and 2 frameshift)
changes; therefore, missense variants were predominant in
PLA2G6-related parkinsonism (Fig. 2; Supporting Informa-
tion File 3). Most PLA2G6 mutations were present in only
one pedigree, whereas 12 occurred in more than one family.
The most frequent variants were c.991G>T (17 pedigrees,
mainly Chinese and Taiwanese),9,10,35,41,43,45-47,59,61,62,64
c.2222G>A (12 Indian, Pakistani and Saudi
families),8,24,29-32,63 and c.1904G>A (10 pedigrees),13,42,43,54
13,42,43,54 with the latter being hitherto detected in only
Japanese kindreds, which suggests a founder effect.
Enzymatic activity of the mutant iPLA2β was docu-
mented in only one included report.45 Transfection of
cDNA encoding PLA2G6 carrying the homozygous
variant c.991G>T into HEK293T cells revealed about
30% of residual protein activity compared with the
wild-type protein.45
Pathology
Brain pathology has been reported in three
cases.16,48,52,53 In one case, brain autopsy revealed cere-
bellar cortical atrophy with severe loss of granule cells,
gliosis in the molecular layer, and to a lesser extent,
Purkinje cell depletion. Cytoarchitecture of the dentate
and inferior olivary nuclei was comparably well pre-
served. There were occasional neuroaxonal spheroids in
the GP, STN, thalamus, and ambiguus nucleus, and fre-
quent ones in the gracile and cuneate nuclei and poste-
rior horns of the spinal cord. There was severe atrophy
of the ventrolateral parts of the SN with better
pigmented neuron preservation medially. The locus
ceruleus showed mild depletion, and the vagus nerve
nucleus in the medulla showed no evidence of severe
neuronal loss. Nevertheless, Lewy bodies were present
in the brainstem nuclei in the tegmentum and frequently
in the less atrophic medial part of the SN, in the
Meynert nucleus, medial temporal lobe, and occasion-
ally in the putamen. Lewy pathology was particularly
widespread across the deep layers of the neocortex
affecting all, including occipital, lobes (Braak stage 6).
There was also very mild tau pathology in the medial
temporal lobe with rare neurofibrillary tangles and
occasional neuropil threads (Fig. 3).16 One patient
underwent brain biopsy of the frontal cortex, which
showed severe Lewy pathology and moderate tau
pathology (neuropil threads).16 Postmortem evaluation
in another case showed widespread cortical and limbic
structure atrophy, Lewy bodies in the SN and locus
ceruleus, Alzheimer’s disease-like pathology, mainly in
the temporal lobe structures, abundant gliosis detected
by glial fibrillary acid protein, and excessive iron accu-
mulation in the reticularis portion of the SN, but also
the GP and ventral forebrain.52,53 No cases hitherto
reported had nerve or rectal biopsy available. Muscle
biopsy was unremarkable in three cases and showed
neurogenic changes and reduced cytochrome oxidase
activity (complex IV) in one case.7,12,16 Skin biopsy,
which, however, did not search for α-synuclein, was
unremarkable in three cases.8,24 Bone marrow aspira-
tion was normal in two cases.8,24
Discussion
We provided in-depth phenotypic and genotypic
characterization of the largest cohort of PLA2G6-
related parkinsonism hitherto reported. Distinct aspects
from this phenogenotypic overview are discussed later.
Although the age of symptom onset ranged between
the first and seventh decades of life, most cases
manifested between late second and third decades of
life. Patients with earlier onset7,12,56 showed over-
lapping clinicoradiological features with ANAD cases
but lacked the typical rapid deterioration in late
childhood,4 and instead had slower symptom progres-
sion with parkinsonism from the second decade of life,
which supports the notion of PLAN phenotypes as a
phenotypic continuum.12,15 Psychiatric features were
frequently observed early in the disease course, often
preceding extrapyramidal manifestations, and were the
only presenting symptoms in one-fifth of the
cohort.10,16,25,29,30,44,59,60 This evidence should warn
clinicians against misdiagnosis of psychiatric disorders
and initiation of potentially detrimental treatments (ie,
antipsychotics) in the context of (at least preclinical)
extrapyramidal involvement.29 Interestingly, onset or
rapid deterioration of symptoms in PLA2G6-related
parkinsonism occurred during pregnancy/postpartum
(cases 2, 3, and 11)30 or in vitro fertilization (case 1) in
five cases. This is in keeping with likely hormone-
related symptom deterioration during pregnancy and,
most often, the perimenopausal and postmenopausal
period previously reported in idiopathic Parkinsonʼs
disease (PD).65 These observations, along with the age
of onset and high prevalence of psychiatric manifesta-
tions, suggest that female individuals with PLA2G6
parkinsonism can be at risk to be misdiagnosed as
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having pregnancy- or postpartum-related psychiatric
morbidity, autoimmune encephalitis, or functional
motor disorders in the early disease stages.
Parkinsonism frequently showed dramatic, albeit
unsustained, response to levodopa. Levodopa efficacy
was most often limited by the occurrence of severe
levodopa-induced dyskinesias, as well as exacerbation
of psychiatric symptoms a few weeks to a few years
after treatment initiation. We suggest that early-onset
levodopa-induced dyskinesias are a tell-tale sign and,
along with other clinicoradiological red flags discussed
in this article, essentially limit the differential diagnosis
to Kufor-Rakeb syndrome. Five patients underwent
bilateral DBS (STN or GPi) with good to excellent
outcome,54,55,57 thus making DBS a potential option in
early disease stages with intractable treatment fluctua-
tions. Dystonia was the second most frequent motor
feature in PLA2G6-related parkinsonism. Isolated foot
dragging was the presenting feature in 10% of
cases,8,24,40,45 thus initially suggesting PRKN-PD.66 We
noticed a high prevalence of extensor truncal dystonia
in our cases and previous literature, thus confirming
dystonic opisthotonus as a hint to suspect NBIA syn-
dromes. Oculogyric crises were also observed,10,30,58
thus expanding the spectrum of disorders possibly man-
ifesting with these paroxysmal dystonic manifesta-
tions.67,68 Finally, oromandibular dystonia seemed less
prevalent than in pantothenate kinase-associated neu-
rodegeneration. Although pyramidal features are not
particularly diriment in early-onset parkinsonian,
pallidopyramidal, or NBIA syndromes, (even subtle)
cerebellar signs could point toward PLA2G6. Finally,
myoclonus was frequently reported a few years into the
disease course, and we first proved its cortical origin on
neurophysiology in case 2.
Cerebellar atrophy was detected on MRI in more
than 40% of cases. Genetic PLA2G6 ablation in mice
causes cerebellar atrophy, with loss of Purkinje cells,
reactive astrogliosis, microglia activation, and up-
regulation of proinflammatory cytokines. Less frequent
and (in most cases) severe degree of cerebellar atrophy
in late-onset PLAN might reflect higher residual iPLA2β
activity. It could also correlate with disease duration
because we documented cerebellar atrophy on follow-
up MRI in three cases where it was not initially
detected. Iron deposition was found in 25% of cases.
Interestingly, it was often not documented on dedicated
MRI-T2*/SWI sequences. When available, dopamine
imaging invariably documented signs of nigrostriatal
degeneration. Notably, in one patient, RAC for post-
synaptic receptor function revealed increased RAC
uptake in the putamen more than in the caudate, thus
indicating a largely presynaptic dopaminergic abnor-
mality as seen in idiopathic PD.25
Pathogenic PLA2G6 mutations causing different
PLAN phenotypes are scattered throughout protein
domains and may therefore impair iPLA2β function
through a variety of loss-of-function mechanisms,
affecting either its enzymatic activity, regulation, or
interactions at the macromolecular level. No mutations
hitherto linked to PLA2G6 parkinsonism affect the pri-
mary structure of iPLA2β domains responsible for its
enzymatic activities. Most of them are nontruncating
and might determine less detrimental effects than trun-
cating variants, which are found more frequently in
INAD/ANAD. As previously suggested, different muta-
tion sites in iPLA2β domains can lead, directly or
indirectly, to different changes in its enzymatic activity,
which might be a critical factor in the phenotypic
heterogeneity of PLAN.69 This is supported by the
observation that all individuals with two null alleles
manifest with INAD, while most patients with ANAD
or late-onset phenotypes carry two missense PLA2G6
mutations.15 Furthermore, it is consistent with the few
biochemical and enzymatic studies available. Engel
et al.69 demonstrated in vitro that mutations associated
with different PLA2G6 phenotypes have different
impact on its catalytic activity. Mutations associated
with INAD/NBIA cause loss of enzyme activity, with
mutant proteins exhibiting less than 20% of wild-type
enzymatic activity in both lysophospholipase and
phospholipase assays. In contrast, three mutations
associated with dystonia-parkinsonism (c.1894C>T,
c.2222G>A, and c.2239C>T) do not impair phospholi-
pase or lysophospholipase catalytic activity. Shi et al.45
documented that the PLA2G6 variant c.991G>T is
associated with approximately 30% residual protein
activity compared with the wild-type iPLA2β. Finally,
Zhou et al.70 found defective activation of endogenous
store-operated Ca2+ and iPLA2β activation in cells from
a patient with familial PD carrying the c.2239C>T
mutation in PLA2G6. Functional studies of the ter-
tiary/quaternary structure of mutant iPLA2β and its
residual enzymatic activity/regulation are needed to fur-
ther explore phenotype–genotype correlations.
Limitations of this study are mainly attributable to its
retrospective nature. Frequencies of clinicoradiological
features were calculated as valid percentages, and this,
or any possible alternative imputation, is not exempt
from risk for underestimation or overestimation.
Furthermore, considerations on the natural disease his-
tory were limited by the lack of precise information on
symptom/sign onset and follow-up in most published
cases. Nevertheless, we are confident this is the most
comprehensive analysis of the largest population with
PLA2G6-related parkinsonism hitherto reported.
Finally, we acknowledge that the search strategy did
not allow to compare PLA2G6 cases with and without
parkinsonism in perspective of gene-specific therapies.
However, we believe that clinicoradiological clues
highlighted by this study might increase the clinical sus-
picion and prompt genetic testing for PLA2G6
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parkinsonism among different etiologies of early-onset
parkinsonism, thus favoring precision medicine in the
not-too-distant future.
In conclusion, biallelic PLA2G6 mutations cause
early-onset parkinsonism with dystonia, pyramidal and
cerebellar signs, myoclonus, and cognitive impairment.
Early psychiatric manifestations and bladder overactivity
are common. Early, severe dyskinesias are a tell-tale sign.
Against this background, irrespective of whether iron depo-
sition is present on brain MRI, the detection of cerebellar
atrophy points toward PLA2G6 among other genetic cau-
ses of early-onset parkinsonian, pallidopyramidal, and
NBIA syndromes. These clinicoradiological features should
prompt PLA2G6 mutation analysis, which might have
considerable therapeutic implications in the near future,
given promising preclinical disease-modifying strategy
development.19
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